Status:
COMPLETED
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Heterozygous Familial Hypercholesterolemia (HeFH)
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with heterozygous familial hypercholester...
Eligibility Criteria
Inclusion
- If female, cannot be of reproductive potential
- Diagnosed with heterozygous familial hypercholesterolemia
- Have been treated with an appropriate and
- stable dose of statin± other lipid-lowering medication(s) for at least 6 weeks
Exclusion
- Previously participated in a study with a cholesteryl ester transfer protein (CETP) inhibitor
- Homozygous familial hypercholesterolemia
- Severe chronic heart failure
- Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery by-pass graft (CABG), unstable angina, or stroke within 3 months
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT01824238
Start Date
May 1 2013
End Date
May 1 2014
Last Update
April 25 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.